Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
28 04 2020
28 04 2020
Historique:
received:
19
11
2019
accepted:
23
02
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
The utility of posttreatment bone marrow biopsy (BMB) histology to confirm complete response (CR) in lymphoma clinical trials is in question. We retrospectively evaluated the impact of BMB on response assessment in immunochemotherapy-treated patients with previously untreated follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the phase 3 Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM; NCT01332968) and A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA; NCT01287741) trials, respectively. Baseline BMB was performed in all patients, with repeat BMBs in patients with a CR by computed tomography (CT) at end of induction (EOI) and a positive BMB at baseline, to confirm response. Positron emission tomography imaging was also used in some patients to assess EOI response (Lugano 2014 criteria). Among patients with an EOI CR by CT in GALLIUM and GOYA, 2.8% and 4.1%, respectively, had a BMB-altered response. These results suggest that postinduction BMB histology has minimal impact on radiographically (CT)-defined responses in both FL and DLBCL patients. In GALLIUM and GOYA, respectively, 4.7% of FL patients and 7.1% of DLBCL patients had a repeat BMB result that altered response assessment when applying Lugano 2014 criteria, indicating that bone marrow evaluation appears to add little value to response assessment in FL; however, its evaluation may still have merit in DLBCL.
Identifiants
pubmed: 32298429
pii: S2473-9529(20)31346-X
doi: 10.1182/bloodadvances.2019001261
pmc: PMC7189300
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Gallium
CH46OC8YV4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1589-1593Informations de copyright
© 2020 by The American Society of Hematology.
Références
Br J Haematol. 2018 Jan;180(2):177-188
pubmed: 29076131
Blood Rev. 2015 Nov;29(6):417-25
pubmed: 26113144
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Br J Haematol. 2017 Oct;179(2):242-245
pubmed: 28677889
Medicine (Baltimore). 2016 Mar;95(9):e2910
pubmed: 26945387
Blood. 2013 Nov 28;122(23):3759-66
pubmed: 24085766
J Clin Oncol. 2017 Nov 1;35(31):3529-3537
pubmed: 28796588
Blood Adv. 2018 Apr 10;2(7):807-816
pubmed: 29636326
Br J Haematol. 2016 Aug;174(3):410-6
pubmed: 27098364
J Clin Oncol. 1999 Apr;17(4):1244
pubmed: 10561185
Clin Cancer Res. 2014 Dec 15;20(24):6398-405
pubmed: 25316810
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Expert Rev Mol Diagn. 2017 Jun;17(6):557-566
pubmed: 28415895
N Engl J Med. 2017 Oct 5;377(14):1331-1344
pubmed: 28976863
J Nucl Med. 2013 Aug;54(8):1244-50
pubmed: 23674577
J Clin Oncol. 2018 Oct 1;36(28):2845-2853
pubmed: 30125215
Blood. 2013 Jul 4;122(1):61-7
pubmed: 23660958